Rallybio

Yahoo Finance • 2 months ago

Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update

Recursion Pharmaceuticals Company shares partnership and clinical updates including $7 million Sanofi milestone and more information on patient populations for REC-1245 (RBM39) and REC-617 (CDK7) SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWS... Full story

Yahoo Finance • 3 months ago

Rallybio to sell interest in REV102 to Recursion Pharmaceuticals for up to $25M

Rallybio (RLYB) announced that it has entered into a definitive agreement to sell its interest in REV102, an ENPP1 inhibitor in preclinical development for the treatment of patients with hypophosphatasia, to joint venture partner Recursion... Full story

Yahoo Finance • 3 months ago

Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia

Salt Lake City, UT, July 08, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of Rallybio’s (NASDAQ: RLYB) full interes... Full story

Yahoo Finance • 3 years ago

5AM Ventures Celebrates 20th FDA Product Approval Investing in Breakthrough Science

SAN FRANCISCO and BOSTON, March 23, 2023 (GLOBE NEWSWIRE) -- 5AM Ventures is pleased that the U.S. Food and Drug Administration (FDA) approved REZZAYO™ (rezafungin for injection) for the treatment of candidemia and invasive candidiasis i... Full story